PH-797804

For research use only.

Catalog No.S2726

30 publications

PH-797804 Chemical Structure

CAS No. 586379-66-0

PH-797804 is a novel pyridinone inhibitor of p38α with IC50 of 26 nM in a cell-free assay; 4-fold more selective versus p38β and does not inhibit JNK2. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) EUR 314 In stock
EUR 167 In stock
EUR 314 In stock
EUR 953 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's PH-797804 has been cited by 30 publications

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description PH-797804 is a novel pyridinone inhibitor of p38α with IC50 of 26 nM in a cell-free assay; 4-fold more selective versus p38β and does not inhibit JNK2. Phase 2.
Targets
p38α [1]
(Cell-free assay)		 p38β [1]
(Cell-free assay)
26 nM 102 nM
In vitro

PH-797804 blocks LPS-induced TNF-α production and p38 kinase activity in the human monocytic U937 cell line, with comparable IC50 of 5.9 nM and 1.1 nM. PH-797804 has no inhibitory effect on either the JNK pathway (c-Jun phosphorylation) or ERK pathway (ERK phosphorylation) in U937 cells at concentrations up to 1 μM. PH-797804 inhibits RANKL- and M-CSF-induced osteoclast formation in a concentration-dependent manner, with IC50 of 3 nM in primary rat bone marrow cells. [1] IC50 values for PH-797804 against the following targets have been determined to be greater than 200 μM (unless specified): CDK2, ERK2, IKK1, IKK2, IKKi, MAPKAP2, MAPKAP3, MKK7 (>100 μM), MNK, MSK (>164 μM), PRAK, RSK2, and TBK1, which means the activity of PH-797804 is specific. [2]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human U937 cells MUjGeY5kfGmxbjDhd5NigQ>? NXTJT|QzUW6qaXLpeIlwdiCxZjDwN|hidHCqYTDrbY5ie2VvZHXw[Y5l\W62IFjTVE0zPyCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hXTl|NzDj[YxteyxiSVO1NF0xNjByMUC1JO69VQ>? M4\Pe|IyPjJyNkm5
human monocytes M4rUbGZ2dmO2aX;uJIF{e2G7 NY\LWmh6SW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCqdX3hckBud26xY4n0[ZMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBNWFNvaX7keYNm\CCWTl\hcJBp[SCycn;keYN1cW:wLDDJR|UxRTBwMECzOEDPxE1? NXH1NpluOjF4MkC2PVk>
human PBMC MWDGeY5kfGmxbjDhd5NigQ>? MYnBcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHnuJIh2dWGwIGDCUWMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBNWFNvaX7keYNm\CCWTl\hcJBp[SC{ZXzlZZNmKHC{ZYTy[YF1\WRiZn;yJFEhcHJiYnXmc5JmKEySUzD0doVifG2nboSgcYVie3W{ZXSgZYZ1\XJiMUigbJJ{NCCLQ{WwQVAvODF3IN88US=> NIjxPZozOTZ2MUKxNS=>

... Click to View More Cell Line Experimental Data
In vivo Orally dosing of PH-797804 effectively inhibits acute inflammatory responses induced by systemically administered endotoxin in both rat and cynomolgus monkeys. PH-797804 treatment for 10 days demonstrates robust anti-inflammatory activity in chronic disease models, significantly reducing both joint inflammation and associated bone loss in streptococcal cell wall-induced arthritis in rats and mouse collagen-induced arthritis. Dose-response analysis resulted in ED50 values of 0.07 mg/kg and 0.095 mg/kg in rat and cynomolgus monkeys, respectively. PH-797804 inhibits LPS-induced TNF-α, IL-6, and MK-2 activity in a dose- and concentration-dependent manner in a human endotoxin challenge model. [1]

Protocol

Kinase Assay:

[1]
- Collapse

P38 kinase assay:

A resin capture assay method is used to determine the phosphorylation of epidermal growth factor receptor peptide (EGFRP) or GST-c-Jun by p38 kinases. Reactions mixtures contain 25 mM HEPES, pH 7.5, 10 mM magnesium acetate, ATP (at the indicated concentration), 0.05 to 0.3 μCi of [γ-33P]ATP, 0.8 mM dithiothreitol, and either 200 μM EGFRP or 10 μM GST-c-Jun for p38α kinase reactions. The reaction is initiated by the addition of 25 nM p38α kinase to give a final volume of 50 μl. The p38αkinase reactions are incubated at 25 °C for 30 minutes. Under these conditions, the formation of product for both p38αkinase is linear with time. The reaction is stopped, and the unreacted [γ-33P]ATP is removed by the addition of 150 μl of AG 1 × 8 ion exchange resin in 900 mM sodium formate, pH 3.0. Once thoroughly mixed, solutions are allowed to stand for 5 minutes. A 50-μl aliquot of head volume containing the phosphorylated substrate is removed from the mixture and transferred to a 96-well plate. MicroScint-40 scintillation cocktail (150 μL) is added to each well and the radioactivity quantities using a TopCount NXT microplate scintillation and luminescence counter.
Cell Research:

[1]
- Collapse
  • Cell lines: Rheumatoid arthritis synovial fibroblast(s)
  • Concentrations: --
  • Incubation Time: --
  • Method:

    Cell viability is evaluated using the 3-(4,5-dimethylthiazol-2-yl)-) diphenyl tetrazolium bromide assay. Absorbance is measured on an ELISA plate reader with a test wavelength of 570 nm and a reference of 630 nm.


    (Only for Reference)
Animal Research:

[1]
- Collapse
  • Animal Models: LPS-induced chronic inflammation rat model
  • Dosages: 0.001-1 mg/kg
  • Administration: Oral gavage 4 hours before LPS administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 96 mg/mL (201.13 mM)
Ethanol 7 mg/mL (14.66 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing. 		5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 477.3
Formula

C22H19BrF2N2O3
CAS No. 586379-66-0
Storage powder
in solvent
Synonyms N/A
Smiles CC1=C(C=C(C=C1)C(=O)NC)N2C(=CC(=C(C2=O)Br)OCC3=C(C=C(C=C3)F)F)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01217918 Completed Drug: 1 mg|Drug: 5 mg|Drug: 10 mg Healthy Pfizer October 2010 Phase 1
NCT00827515 Withdrawn Drug: PH797804 Pain Pfizer February 2009 Phase 1
NCT00614705 Completed Drug: PH-797804|Drug: Placebo Neuralgia Postherpetic Pfizer April 2008 Phase 2
NCT00620685 Completed Drug: Placebo|Drug: PH-797804 Arthritis Rheumatoid Pfizer March 2008 Phase 2
NCT00383188 Completed Drug: placebo|Drug: PH-797804 Arthritis Rheumatoid Pfizer December 2006 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
selleck catalog

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

  • Pan p38 MAPK Inhibitor

    SB202190 (FHPI) : Pan-p38α/β inhibitor, IC50=50 nM/100 nM.

  • Most Potent p38 MAPK Inhibitor

    Skepinone-L New : p38α-MAPK, IC50=5 nM.

  • p38 MAPK Inhibitor in Clinical Trial

    VX-702 : Phase II for Rheumatoid Arthritis.

  • Newest p38 MAPK Inhibitor

    Skepinone-L New : Selective p38α-MAPK inhibitor with IC50 of 5 nM.

Related p38 MAPK Products

  • Pexmetinib (ARRY-614) New

    Pexmetinib (ARRY-614) is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1.

  • SB239063 New

    SB239063 is a potent and selective p38 MAPKα/β inhibitor with IC50 of 44 nM, showing no activity against the γ- and δ-kinase isoforms.

  • Ravoxertinib (GDC-0994) New

    Ravoxertinib (GDC-0994) is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.

  • SB203580

    SB203580 (RWJ 64809, PB 203580) is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μM in THP-1 cells, 10-fold less sensitive to SAPK3(106T) and SAPK4(106T) and blocks PKB phosphorylation with IC50 of 3-5 μM. SB203580 induces mitophagy and autophagy.

    Features:First reported p38 inhibitor.

  • Doramapimod (BIRB 796)

    Doramapimod (BIRB 796) is a pan-p38 MAPK inhibitor with IC50 of 38 nM, 65 nM, 200 nM and 520 nM for p38α/β/γ/δ in cell-free assays, and binds p38α with Kd of 0.1 nM in THP-1 cells, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2.

    Features:The first p38 MAPK inhibitor to be tested in a phase III clinical trial.

  • SB202190 (FHPI)

    SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo. SB202190 inhibits endothelial cell apoptosis via induction of autophagy and heme oxygenase-1. SB202190 significantly suppresses Erastin‐dependent ferroptosis.

  • Ralimetinib (LY2228820) dimesylate

    Ralimetinib (LY2228820) dimesylate is a novel and potent inhibitor of p38 MAPK with IC50 of 7 nM in a cell-free assay, does not alter p38 MAPK activation. Phase 1/2.

  • Losmapimod (GW856553X)

    Losmapimod (GW856553X, GW856553, GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively. P38 MAPKs are involved in cell differentiation, apoptosis and autophagy. Phase 3.

  • VX-702

    VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.

    Features:Highly selective, orally active inhibitor of p38 MAPK.

  • TAK-715

    TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, 28-fold more selective for p38α over p38β, no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK1. Phase 2.

Tags: buy PH-797804 | PH-797804 supplier | purchase PH-797804 | PH-797804 cost | PH-797804 manufacturer | order PH-797804 | PH-797804 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID